Better Therapeutics- Tradeable Rights - March 2021 Accounts Payable

As of the most recent data (September 2023), MCADR shows a accounts payable of $2.3M. That compares with $1.3M in the prior-year period — up 83.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MCADR's accounts payable is now $2.3M (was $1.3M) — a 83.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Better Therapeutics- Tradeable Rights - March 2021 is outperforming or lagging.

Tracking MCADR's accounts payable over time shows whether Better Therapeutics- Tradeable Rights - March 2021 is scaling, shrinking, or reshaping that part of the business. The current reading is $2.3M That compares with $1.3M in the prior-year period — up 83.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Better Therapeutics- Tradeable Rights - March 2021's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.3M) with ownership activity and broader fundamentals.